May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Pharmacotherapy Compliance in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Author Affiliations & Notes
  • C. E. Traverso
    Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Clinica Oculistica, University of Genova, Genova, Italy
  • J. G. Walt
    Global Health Outcomes Strategy and Research, Allergan Inc., Irvine, California
  • T. H. Chiang
    Global Health Outcomes Strategy and Research, Allergan Inc., Irvine, California
  • L. S. Stern
    Analytica International, New York, New York
  • J. J. Doyle
    Analytica International, New York, New York
  • M. Dolgister
    Analytica International, New York, New York
  • Footnotes
    Commercial Relationships C.E. Traverso, None; J.G. Walt, Allergan Inc., E; T.H. Chiang, Allergan Inc., E; L.S. Stern, Analytica International, E; J.J. Doyle, Analytica International, E; M. Dolgister, Analytica International, E.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5578. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. E. Traverso, J. G. Walt, T. H. Chiang, L. S. Stern, J. J. Doyle, M. Dolgister; Pharmacotherapy Compliance in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5578.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To compare rates of pharmacotherapy compliance in patients with ocular hypertension (OH) and patients with primary open-angle glaucoma (POAG).

Methods:: Retrospective analysis of a nationally representative, multi-managed health plan database (PharMetrics; 1998-2005) of patients with OH and POAG who had at least one year of continuous enrollment. Medication coverage was defined as the percent of days during which a patient was in possession of IOP-lowering therapy over the first year of follow-up (medication coverage=number of covered days/365). Analyses were conducted in all patients and subsequently in patients with at least one prescription for IOP-lowering medication during the first year of follow-up.

Results:: The study population consisted of 36,767 OHTN patients and 72,412 POAG patients. POAG patients had slightly longer mean total years of follow-up (3.5, SD=1.4) than OHTN patients (3.3, SD=1.4; p<0.0001). Unadjusted, the mean medication coverage for the POAG cohort was significantly higher (37%, SD=0.32) than the mean coverage for the OHTN cohort (5%, SD=0.16; p<0.0001). Of the OHTN cohort, only 13.1% of patients filled at least one prescription, as compared to 73.2% of the POAG cohort. Of patients who filled at least one prescription, mean coverage was 50% for the POAG cohort (SD=0.26) and 40% for the OHTN cohort (SD=0.25; p<0.0001).

Conclusions:: Patients with POAG, a more severe condition, were significantly more compliant with pharmacotherapies than patients with OHTN. It is important to implement strategies to help improve patient compliance prior to occurrence of more severe disease.

Keywords: vascular occlusion/vascular occlusive disease • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×